D. Kim

457 total citations
16 papers, 347 citations indexed

About

D. Kim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, D. Kim has authored 16 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in D. Kim's work include Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer therapeutics and mechanisms (5 papers). D. Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer therapeutics and mechanisms (5 papers). D. Kim collaborates with scholars based in United States, South Korea and Italy. D. Kim's co-authors include Alice T. Shaw, Anna Polli, Lucio Crinò, Benjamin Solomon, D. Ross Camidge, Tommaso De Pas, Pasi A. Jänne, Gregory J. Riely, Pan‐Chyr Yang and Tony Mok and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

D. Kim

16 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Kim United States 8 323 275 126 52 31 16 347
J.C.-H. Yang Taiwan 5 281 0.9× 263 1.0× 94 0.7× 46 0.9× 22 0.7× 12 353
F. Bustin Belgium 6 354 1.1× 336 1.2× 122 1.0× 47 0.9× 33 1.1× 11 459
L. Paz-Ares Spain 9 215 0.7× 291 1.1× 97 0.8× 40 0.8× 38 1.2× 51 374
M.R. García Campelo Spain 9 301 0.9× 284 1.0× 119 0.9× 90 1.7× 32 1.0× 35 387
Minal Mehta United States 9 310 1.0× 290 1.1× 93 0.7× 85 1.6× 19 0.6× 19 383
Marc Chioda United States 9 185 0.6× 181 0.7× 77 0.6× 42 0.8× 25 0.8× 14 276
Laura Emerson United States 5 285 0.9× 246 0.9× 89 0.7× 76 1.5× 29 0.9× 5 354
Rossella Messina United States 3 233 0.7× 182 0.7× 75 0.6× 55 1.1× 27 0.9× 6 269
Scott Barker United States 6 175 0.5× 155 0.6× 57 0.5× 72 1.4× 23 0.7× 19 259
You Lu China 9 298 0.9× 251 0.9× 59 0.5× 46 0.9× 19 0.6× 22 338

Countries citing papers authored by D. Kim

Since Specialization
Citations

This map shows the geographic impact of D. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Kim more than expected).

Fields of papers citing papers by D. Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Kim. The network helps show where D. Kim may publish in the future.

Co-authorship network of co-authors of D. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of D. Kim. A scholar is included among the top collaborators of D. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Kim. D. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Mazières, Julien, Laura Iadeluca, Alice T. Shaw, et al.. (2021). MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC. Journal of Thoracic Oncology. 16(3). S175–S176. 2 indexed citations
2.
Ramalingam, Suresh S., Ferdinandos Skoulidis, Ramaswamy Govindan, et al.. (2021). P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100. Journal of Thoracic Oncology. 16(10). S1123–S1123. 37 indexed citations
3.
Chen, Joseph, Alessandra Bearz, D. Kim, et al.. (2019). P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S392–S393. 2 indexed citations
4.
Tan, Aaron C., Tony Mok, D. Kim, et al.. (2019). P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S836–S837. 5 indexed citations
5.
Ou, S.‐H.I., Byoung Chul Cho, D. Kim, et al.. (2018). OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(12). S1047–S1047. 3 indexed citations
6.
Linehan, W. Marston, D. Kim, Alexander Drilon, et al.. (2018). OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC. Journal of Thoracic Oncology. 13(10). S322–S322. 5 indexed citations
7.
Solomon, Benjamin, Jean‐Charles Soria, Fiona Blackhall, et al.. (2017). P1.01-016 Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib. Journal of Thoracic Oncology. 12(11). S1898–S1899. 1 indexed citations
8.
Mok, Tony, D. Ross Camidge, S. Gadgeel, et al.. (2017). MA 07.01 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial. Journal of Thoracic Oncology. 12(11). S1826–S1826. 2 indexed citations
9.
Mok, Tony, Solange Peters, D. Ross Camidge, et al.. (2017). JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial. Journal of Thoracic Oncology. 12(11). S1739–S1740. 1 indexed citations
10.
Shaw, Alice T., Ranee Mehra, Enriqueta Felip, et al.. (2014). Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study. Annals of Oncology. 25. iv455–iv455. 28 indexed citations
11.
Kim, D., James Chih‐Hsin Yang, Darren A.E. Cross, et al.. (2014). Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm). Annals of Oncology. 25. iv152–iv152. 18 indexed citations
12.
Kim, D., Ranee Mehra, Enriqueta Felip, et al.. (2014). Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1. International Journal of Radiation Oncology*Biology*Physics. 90(5). S33–S34. 13 indexed citations
13.
Felip, Enriqueta, D. Kim, Ranee Mehra, et al.. (2014). Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. Annals of Oncology. 25. iv456–iv456. 32 indexed citations
14.
Besse, Benjamin, Ravi Salgia, Benjamin Solomon, et al.. (2012). Visual Disturbances in Patients (PTS) with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib. Annals of Oncology. 23. ix416–ix416. 9 indexed citations
15.
Kim, D., Myung‐Ju Ahn, Pan‐Chyr Yang, et al.. (2012). Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 23. ix402–ix402. 57 indexed citations
16.
Crinò, Lucio, D. Kim, Gregory J. Riely, et al.. (2011). Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.. Journal of Clinical Oncology. 29(15_suppl). 7514–7514. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.C.-H. Yang Breakdown of academic impact, for papers by F. Bustin Breakdown of academic impact, for papers by L. Paz-Ares Breakdown of academic impact, for papers by M.R. García Campelo Breakdown of academic impact, for papers by Minal Mehta Breakdown of academic impact, for papers by Marc Chioda Breakdown of academic impact, for papers by Laura Emerson Breakdown of academic impact, for papers by Rossella Messina Breakdown of academic impact, for papers by Scott Barker Breakdown of academic impact, for papers by You Lu
Rankless by CCL
2026